SCHEMBL3344592

SCHEMBL3344592

COC(=O)c1cc(OCc2ccccc2)cc(Oc2ccc(C(=O)N3CCC3)cc2Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.48
ALDH1A1 P00352 6/20 0.47
NPC1 O15118 6/20 0.47
RAB9A P51151 6/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TP53 P04637 2/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 1/20 0.47
HSD17B10 Q99714 1/20 0.46
USP2 O75604 1/20 0.45
RECQL P46063 1/20 0.45
MAPT P10636 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GPR55 Q9Y2T6 1/20 0.44
KCNH2 Q12809 1/20 0.44
MGLL Q99685 1/20 0.43
HSD11B1 P28845 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A4 P31645 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2656263 0.91 MEN1 (0.54) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2659538 0.83 GCK (0.57) KCNH2
SCHEMBL9071180 0.79 GCK (0.51) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL2655994 0.76 ALDH1A1 (0.41) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL2074500 0.76 ALDH1A1 (0.41) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL1647491 0.76 NPC1 (0.57) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL391547 0.76 MEN1 (0.71) HPGDNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL1646608 0.75 HPGD (0.56) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL3231604 0.75 MRGPRX4 (0.63) HPGDALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL183994 0.73 LMNA (0.70) HPGDNPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160286-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES ASTRAZENECA UK LIMITED AB (SE) 2010-06-24 US disclosed
US-20100160286-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES ASTRAZENECA UK LIMITED AB (SE) 2010-06-24 US disclosed
US-20100160286-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES ASTRAZENECA UK LIMITED AB (SE) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160286-A1 HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES GCK, GCKR, HK1 HPGD 522/4885ALDH1A1 789/4885NPC1 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.